STAT Plus: What’s next in NASH? 6 things to know following the failure of Gilead’s lead drug for fatty liver disease

By ADAM FEUERSTEIN

ADOBE

If there’s any negative read-through between recent trials, it might be the reminder that improving liver scarring (fibrosis) in NASH patients is difficult.

READ MORE